Lead CAR-T Program
Glioblastoma (GBM)
Key Facts
About Kiragen Bio
KiraGen Bio is a preclinical-stage biotech founded in 2020, pioneering a novel approach to cell therapy for solid tumors. The company's core innovation is the development of allogeneic, multiplex-edited CAR-T cells equipped with 'TME-Guards'—multiple genetic edits that function like 'noise-cancelling headphones' to block the suppressive signals from the tumor microenvironment that typically cause therapy failure. Leveraging its AI-driven KiraLOGIC platform for target and edit optimization, KiraGen aims to create more durable and effective off-the-shelf therapies, starting with a lead program in glioblastoma. The company is privately held, backed by strategic investors, and led by a team with deep experience in cell therapy, gene editing, and computational biology.
View full company profileTherapeutic Areas
Other Glioblastoma (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| GlioGuard Therapeutic & Diagnostic System | GlioGuard | Pre-clinical |
| DOC1021 | Diakonos Oncology | Phase 2 |
| GBM Immunotherapy (with SandboxAQ) | iOncologi | Pre-clinical |
| DCVax®-L | Northwest Biotherapeutics | Phase 3 |
| Lucicebtide (ST101) | Sapience Therapeutics | Phase 2 |
| Glioblastoma Assay Optimization (CPRIT Grant) | SingleCell Biotechnology | Pre-clinical |
| Lead Program (unspecified) | BlueHaven Therapeutics | Preclinical |
| TLX101 (Pixclara® / 131I-IPA) | Telix Pharmaceuticals | Phase 3 |
| Paxalisib | Kazia Therapeutics | Phase II/III |